NGLFINE NGL Fine-Chem Q4 FY25 results (Jan–Mar 2025) and concall
NGL Fine Chem reported a challenging Q4 FY25 with significant margin compression and a 49% decline in FY25 PAT, primarily due to heightened competition, subdued realizations, and geopolitical issues. Despite these headwinds, the company successfully commercialized Phase 1 of its capex project and remains committed to strategic initiatives, including regulated market entry and process reengineering, with meaningful sales from new capacities expected from FY27.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 93 | 89 | 95 |
| EBITDA | 12 | 5 | 6 |
| Net profit | 10 | 1 | 1 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
